Dr. Francis J. Cuevas

Claim this profile

Ascension Southeast Wisconsin Hospital - Elmbrook Campus

Studies Cancer
Studies Colorectal Cancer
11 reported clinical trials
24 drugs studied

Area of expertise

1Cancer
Francis J. Cuevas has run 5 trials for Cancer. Some of their research focus areas include:
Stage II
Stage I
Stage IV
2Colorectal Cancer
Francis J. Cuevas has run 3 trials for Colorectal Cancer. Some of their research focus areas include:
Stage III
Stage IV
MLH1 positive

Affiliated Hospitals

Image of trial facility.
Ascension Southeast Wisconsin Hospital - Elmbrook Campus
Image of trial facility.
Ascension Saint Francis - Reiman Cancer Center

Clinical Trials Francis J. Cuevas is currently running

Image of trial facility.

Chemotherapy + Bevacizumab + Atezolizumab

for Colorectal Cancer

This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop or slow colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
Recruiting2 awards Phase 31 criteria
Image of trial facility.

Sotorasib

for Non-Small Cell Lung Cancer

This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Recruiting2 awards Phase 219 criteria

More about Francis J. Cuevas

Clinical Trial Related7 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Francis J. Cuevas has experience with
  • Atezolizumab
  • Nivolumab
  • Fluorouracil
  • Leucovorin
  • Oxaliplatin
  • Duloxetine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Francis J. Cuevas specialize in?
Francis J. Cuevas focuses on Cancer and Colorectal Cancer. In particular, much of their work with Cancer has involved Stage II patients, or patients who are Stage I.
Is Francis J. Cuevas currently recruiting for clinical trials?
Yes, Francis J. Cuevas is currently recruiting for 4 clinical trials in Brookfield Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Francis J. Cuevas has studied deeply?
Yes, Francis J. Cuevas has studied treatments such as Atezolizumab, Nivolumab, Fluorouracil.
What is the best way to schedule an appointment with Francis J. Cuevas?
Apply for one of the trials that Francis J. Cuevas is conducting.
What is the office address of Francis J. Cuevas?
The office of Francis J. Cuevas is located at: Ascension Southeast Wisconsin Hospital - Elmbrook Campus, Brookfield, Wisconsin 53045 United States. This is the address for their practice at the Ascension Southeast Wisconsin Hospital - Elmbrook Campus.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.